Breast cancer: New data on cohort with recurrence score 26-100 shows 93% cancer-free rate at 5 years

In the prospective TAILORx trial, 93% of women with hormone-sensitive, HER2-negative, axillary node-negative breast cancer and a high Recurrence Score 26-100 were estimated to be cancer-free at five years. This outcome was much better than expected with endocrine therapy alone. The finding adds to limited data on outcomes with a high RS of 26-100, treated with taxane and/or anthracycline-containing chemotherapy plus endocrine therapy. It adds to the body of evidence supporting use of the RS.

Read more

Mesothelioma trial suggests immunotherapy as an alternative to chemotherapy

Patients with mesothelioma may gain similar benefit from immunotherapy as chemotherapy, and good responders may provide important clues to novel treatment for the thousands of new cases each year. New data highlight the need to understand the biological mechanisms whereby mesothelioma, which is incurable, adapts to immunotherapy in some patients but not in others, resulting in variations in treatment response.

Read more

Trial finds high-dose radiation effective for men whose prostate cancer has spread

A randomized clinical trial of targeted, high-dose radiation for men with oligometastatic prostate cancer has shown the treatment to be an effective and safe option for patients who wish to delay hormone-suppression therapy. The phase II trial found that radiation therapy can generate an immune system response not previously believed possible in this type of cancer.

Read more